Cost analysis of candida infection among surgical intensive care unit patients

Clinical Drug Investigation

Volumn 12, Issue 4, 1996, Pages 176-180

  Goff, Debra A ^a   Sierawski, Sondra J ^a   Fass, Robert J ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CORTICOSTEROID THERAPY; DRUG COST; FEVER; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; HYPOTHERMIA; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SURGERY;

EID: 0030001592     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612040-00002     Document Type: Article

References (18)

1. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991: 91 Suppl. 3B: 86S-9S
2. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21
3. Beck-Sugué CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-51
4. Jarvis WR, Martone WJ. Predominant pathogens in hospital infection. J Antimicrob Chemother 1992; 29 Suppl. A: 19-24
5. Komshian SV, Uwaydah AK, Sobel JD, et al. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379-90
6. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5
7. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525-32
8. Sobel JD. Candida infections in the intensive care unit. Crit Care Clin 1988; 4: 325-44
9. Edwards Jr JE. Candida species. In: Mandell GL, Douglas Jr RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 1943-58
10. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-601
11. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149: 2349-53
12. Eubanks PJ, de Virgilio C, Klein S, et al. Candida sepsis in surgical patients. Am J Surg 1993; 166: 617-20
13. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274 (8): 639-44
14. Gaines JD, Remington JS. Diagnosis of deep infection with Candida: a study of Candida precipitins. Arch Intern Med 1973; 132: 699-702
15. Sugar AM. Problems in the diagnosis of invasive candidiasis in the immunocompromised patient. In: Richardson RG, editor. Opportunistic fungal infections: focus on fluconazole. International Congress and Symposium Series No. 153. London: Royal Society of Medicine Services Ltd, 1989: 17-24
16. Edwards Jr JE. Candidemia and Candida catheter-associated sepsis. In: Holmberg K, Meyer RD, editors. Diagnosis and therapy of systemic fungal infections. New York: Raven Press, 1989: 39-46
17. Fass RJ, Goff DA, Sierawski SJ. Candida infections in the surgical intensive care unit (SICU). J Antimicrobial Chemother. In press
18. Dasta JF, Armstrong DK. Pharmacoeconomic impact of critically ill surgical patients. Drug Intell Clin Pharm 1988; 22: 994-8